Dr. Reddy's Laboratories Ltd.

322 articles with Dr. Reddy's Laboratories Ltd.

• Dr. Reddy's Laboratories Announces the Re-Launch of Its Buprenorphine and Naloxone Sublingual Film after Favorable Ruling in Patent Litigation

  2/20/2019

  The re-launch comes on the heels of a favorable decision issued by the United States Court of Appeals for the Federal Circuit concluding that Indivior had not shown that it is likely to succeed on its claim that Dr. Reddy’s product infringes U.S. Patent No. 9,931,305.

• Dr. Reddy's Laboratories launches Tadalafil Tablets USP in the U.S. Market

  2/12/2019

  Dr. Reddy’s Laboratories Ltd. announced the launch of Tadalafil Tablets USP, a therapeutic equivalent generic version of Adcirca Tablets in the United States market, approved by the U.S. Food and Drug Administration.

• 

  BioSpace Movers and Shakers: Feb. 8

  2/8/2019

  In this week's edition of Movers and Shakers, biopharma companies tap executives to serve in various leadership roles.

• Dr. Reddy's Laboratories Continues its Voluntary Nationwide Recall of Levetiracetam in 0.54% Sodium Chloride Injection 1500mg/100mL Due to Mislabeling

  2/4/2019

  Dr. Reddy’s Laboratories Ltd. announced that its wholly owned subsidiary, Dr Reddy’s Laboratories, Inc, is continuing its voluntary nationwide recall of lot ABD807 of Levetiracetam in 0.54% Sodium Chloride Injection, 1,500 mg/100 mL single-dose infusion bags to the hospital level in U.S.A.

• Dr. Reddy’s Q3 FY19 Financial Results

  2/1/2019

  Dr. Reddy’s Laboratories Ltd. announced its consolidated financial results for the quarter ended December 31, 2018 under International Financial Reporting Standards.

• Dr. Reddy's Announces the Appointment of Marc Kikuchi to Lead Its Generics Business in North America

  2/1/2019

  Dr. Reddy’s Laboratories Ltd. announced the appointment of Marc Kikuchi as Chief Executive Officer, North America Generics.

• Dr. Reddy's Laboratories and Its U.S. Subsidiary, Promius Pharma, Announce FDA Approval for TOSYMRA™ (Sumatriptan Nasal Spray) 10 mg, in the U.S. Market

  1/28/2019

  Dr. Reddy's Laboratories Ltd. and its subsidiary, Promius Pharma, LLC announced the approval of TOSYMRA (previously known as DFN-02) by the U.S. Food and Drug Administration (FDA).

• Dr. Reddy's Laboratories Announces the Launch of Propofol Injectable Emulsion, USP in the U.S. Market

  1/24/2019

  Dr. Reddy’s Laboratories Ltd. today announced the launch of Propofol Injectable Emulsion, USP, a therapeutic equivalent generic version of DIPRIVAN (propofol) Injectable Emulsion, USP, approved by the U.S. Food and Drug Administration (USFDA).

• 

  Companies Continue to Develop Treatments for Opioid Addiction

  1/22/2019

  As opioid lawsuits continue to wind through the courts, some drugmakers are focused on developing treatments for opioid addiction.

• Dr. Reddy's to Release Q3 FY19 Results on February 1, 2019

  1/11/2019

  Dr. Reddy's Laboratories will announce results for the quarter ended December 31, 2018 on Friday, February 1, 2019 after the Board Meeting

• Dr. Reddy's Laboratories Limited to Present at the 37th Annual J.P. Morgan Healthcare Conference

  1/7/2019

  Dr. Reddy’s Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced that the Company will be presenting at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, California.

• Dr. Reddy's Laboratories Announces the Launch of Sevelamer Carbonate for Oral Suspension in the U.S. Market

  12/27/2018

  Dr. Reddy’s Laboratories Ltd. today announced the launch of Sevelamer Carbonate for Oral Suspension, in 0.8 g and 2.4 g packets, a therapeutic equivalent generic version of Renvela (sevelamer carbonate) for Oral Suspension, approved by the U.S. Food and Drug Administration (USFDA).

• Dr. Reddy's Laboratories Launches Aspirin and Extended-Release Dipyridamole Capsules in the U.S. Market

  12/24/2018

  Dr. Reddy’s Laboratories Ltd today announced the launch of Aspirin and Extended-Release Dipyridamole Capsules, a therapeutic equivalent generic version of Aggrenox (aspirin and extended-release dipyridamole) Capsules in the United States market from the U.S. Food and Drug Administration (USFDA).

• Dr. Reddy’s announces the launch of over-the-counter store brand equivalent of Prilosec OTC® (Omeprazole Delayed-Release) Tablets, 20 mg in the U.S. Market

  12/11/2018

  Dr. Reddy’s Laboratories Ltd. announced today the launch of Omeprazole Delayed-Release Tablets, 20 mg, an over-the-counter (OTC) store-brand equivalent of Prilosec® OTC (omeprazole delayed-release) Tablets, 20 mg, in the United States market as approved by the U.S. Food and Drug Administration (USFDA).

• Dr. Reddy's Laboratories Announces the Launch of Chlorthalidone Tablets, USP in the U.S. Market

  11/28/2018

  Dr. Reddy’s Laboratories Ltd. today announced the launch of Chlorthalidone Tablets USP, 25 mg and 50 mg, a therapeutic equivalent generic version of Hygroton (chlorthalidone) Tablets, approved by the U.S. Food and Drug Administration (USFDA).

• Indivior to Host Conference Call on December 18th; Previously-Scheduled Capital Markets Day to be Held in February 2019

  11/27/2018

  Indivior PLC today announced that in light of the recent decision by the Court of Appeals for the Federal Circuit (CAFC) vacating the preliminary injunction against Dr. Reddy's Laboratories (DRL) the Company will host a conference call on December 18th to discuss its strategy and contingency plans.

• Dr. Reddy's Laboratories Announces Favorable Outcome in Buprenorphine and Naloxone Sublingual Film Patent Litigation

  11/21/2018

  Dr. Reddy’s Laboratories Ltd. announced today that the United States Court of Appeals for the Federal Circuit issued a decision in favor of Dr. Reddy’s Laboratories Inc., concluding that Indivior had not shown that it is likely to succeed on the merits of its infringement case on U.S. Patent No. 9,931,305.

• Dr. Reddy's Laboratories Announces the Launch of Atomoxetine Capsules, USP in the U.S. Market

  10/31/2018

  Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Atomoxetine Capsules, USP, a therapeutic equivalent generic version of Strattera® (atomoxetine) Capsules in the United States market approved by the U.S. Food and Drug Administration (USFDA).

• Dr. Reddy’s Q2 & H1 FY19 Financial Results

  10/26/2018

  Dr. Reddy’s Laboratories Ltd. today announced its consolidated financial results for the quarter and half year ended September 30, 2018 under International Financial Reporting Standards (IFRS).

• Dr. Reddy's Laboratories Announces the Sale of Its API Manufacturing Business Unit in Jeedimetla, Hyderabad

  10/15/2018

  Dr. Reddy’s Laboratories Ltd. today announced that it has entered into a definitive agreement for the sale of its API manufacturing business unit located in Jeedimetla, Hyderabad, to Therapiva Private Ltd., an emerging generics pharmaceutical company.